NCT05311566View on ClinicalTrials.gov

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 27, 2022

Primary Completion Date

March 27, 2023

Study Completion Date

March 27, 2026

Conditions
Cervical CarcinomaChemoradiotherapyAnti-programmed Cell Death Receptor 1ImmunotherapyImmune Checkpoint InhibitorSurvival OutcomesAdverse EventsEarly Stage Cervical CancerLocally Advanced Cervical Cancer
Interventions
COMBINATION_PRODUCT

Camrelizumab plus Concurrent chemoradiotherapy

Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy. After completing 6\~8weeks of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until disease progression or unacceptable toxicity.

Trial Locations (1)

100730

RECRUITING

Lei Li, Beijing

All Listed Sponsors
lead

Lei Li

OTHER